8-K: STERIS plc Reports Strong First Quarter Results, Reaffirms Fiscal 2025 Outlook

STERIS plc announced an 8% increase in total revenue and a 6% growth in constant currency organic revenue for the first quarter of fiscal year 2025, with adjusted EPS rising to $2.03.

Summary

• STERIS plc reported its financial results for the first quarter of fiscal year 2025, ending June 30, 2024.
• Total revenue from continuing operations increased by 8% to $1.3 billion, compared to $1.2 billion in the same quarter of the previous year.
• Constant currency organic revenue grew by 6% in the first quarter.
• As reported net income was $139.9 million, or $1.41 per share, up from $130.6 million, or $1.31 per share, in the prior year.
• Adjusted net income was $201.7 million, or $2.03 per diluted share, compared to $182.5 million, or $1.84 per diluted share, in the first quarter of fiscal 2024.
• Healthcare revenue increased by 10% to $901.2 million, driven by growth in consumables and services, partially offset by a decline in capital equipment.
• Applied Sterilization Technologies (AST) revenue grew by 7% to $249.8 million, with growth in both service and capital equipment.
• Life Sciences revenue decreased by 2% to $128.5 million due to the divestiture of the CECS business, but constant currency organic revenue increased by 4%.
• Net cash provided by operations was $303.7 million, while free cash flow was $195.7 million, a decrease due to the timing of capital spending.
• The company reiterated its fiscal 2025 outlook, expecting a 6.5-7.5% increase in as reported revenue and a 6-7% increase in constant currency organic revenue.
• Adjusted earnings per diluted share are projected to be between $9.05 and $9.25 for fiscal 2025.
• Capital expenditures are anticipated to be approximately $360 million, and free cash flow is expected to be around $700 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increased earnings, and reaffirmed guidance. While there are some minor negatives, the overall tone is optimistic and indicates a healthy financial performance.

Positives

• STERIS experienced positive momentum across all segments.
• Healthcare segment saw strong growth in consumables and services.
• AST segment showed growth in both service and capital equipment revenue.
• Life Sciences segment demonstrated organic growth despite a divestiture.
• The company is confident in its ability to deliver on its full-year guidance.
• Net cash provided by operations increased to $303.7 million from $281.1 million in the prior year.

Negatives

• Life Sciences revenue decreased by 2% due to the divestiture of the CECS business.
• Healthcare capital equipment revenue declined by 10%.
• Free cash flow decreased to $195.7 million from $214.5 million due to the timing of capital spending.
• Life Sciences saw a 15% decline in capital equipment revenue and a 17% decline in service revenue.

Risks

• The company faces risks related to market conditions, political events, and competitive factors.
• Changes in laws, government regulations, and regulatory actions could impact the company's performance.
• International unrest, economic downturns, and currency fluctuations could affect the company's results.
• There is a risk of reduced demand for the company's products and services.
• Supply chain issues could lead to delays in manufacturing and shipping.
• The company's indebtedness could limit financial flexibility.
• Changes in tax laws could increase consolidated tax liabilities.
• The company faces risks related to the integration of acquired businesses.

Future Outlook

The company expects as reported revenue from continuing operations to increase 6.5-7.5% and constant currency organic revenue to increase 6-7% for fiscal 2025. Adjusted earnings per diluted share are anticipated to be in the range of $9.05 to $9.25.

Management Comments

• We are pleased with the start to our new fiscal year and continue to experience positive momentum across each of our segments, said Dan Carestio, President and CEO of STERIS.
• With one quarter behind us, we are reiterating our outlook for fiscal 2025 and are confident in our ability to deliver on our full year guidance.

Industry Context

This announcement reflects the ongoing demand for healthcare and sterilization products and services, with STERIS showing growth in key areas. The company's performance is indicative of the broader trends in the medical device and life sciences industries, where recurring revenue streams from consumables and services are increasingly important.

Comparison to Industry Standards

• STERIS's 8% revenue growth is solid compared to other medical device companies, such as Medtronic and Stryker, which have seen growth in the mid-single digits in recent quarters.
• The 6% constant currency organic growth is also competitive, indicating strong underlying demand for STERIS's products and services.
• The adjusted EPS of $2.03 is a positive result, showing the company's ability to manage costs and improve profitability.
• The company's performance in the healthcare segment, with a 10% revenue increase, is particularly strong, outpacing some of its competitors in this area.
• The free cash flow of $195.7 million is a decrease compared to the prior year, but the company has provided guidance for $700 million for the full year, which is a positive sign.

Stakeholder Impact

• Shareholders will likely view the results positively due to the revenue growth and increased earnings.
• Employees may benefit from the company's continued success and growth.
• Customers will continue to receive products and services from a financially stable company.
• Suppliers will likely see continued business with STERIS.
• Creditors will be reassured by the company's strong financial performance.

Next Steps

• STERIS management will host a conference call on August 7, 2024, to discuss the financial results.
• The company will continue to execute its fiscal 2025 plan and monitor market conditions.

Key Dates

Keywords

STERIS, Financial Results, Revenue, Earnings Per Share, Healthcare, Applied Sterilization Technologies, Life Sciences, Organic Growth, Constant Currency, Free Cash Flow, Fiscal 2025, Medical Devices, Infection Prevention